December 1976

Developmental Therapy in Adult Acute Leukemia

Author Affiliations

From the Departments of Developmental Therapeutics (Drs Freireich, Bodey, McCredie, Hersh, Hart, Gutterman, Rodriguez, and Hester) and Biomathematics (Dr Gehan and Mr Smith), University of Texas Cancer System Center, M.D. Anderson Hospital and Tumor Institute, Houston.

Arch Intern Med. 1976;136(12):1417-1421. doi:10.1001/archinte.1976.03630120063017

The diagnosis of acute leukemia was a virtual death sentence less than 30 years ago. A patient with this diagnosis had an expected median life span of less than three months, and had a greater than 90% probability of being dead within a year of diagnosis. It rated as one of the most dreaded and most malignant of the malignant diseases. The discovery of the first antimetabolite, methotrexate, and the subsequent discovery of other new effective drugs led to rapid improvement in the outlook for children with acute leukemia.1 By 1965, virtually every child with that diagnosis would respond to treatment with complete hematologic and clinical remission, and a substantial proportion would be expected to have prolonged survival.2 Several studies have suggested that 10% to 30% of patients might be surviving more than five years after diagnosis and might even be considered as potentially curable.3,4 However, the

First Page Preview View Large
First page PDF preview
First page PDF preview